AGTC Stock Overview
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.
Applied Genetic Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.27|
|52 Week High||US$3.18|
|52 Week Low||US$0.26|
|1 Month Change||-31.60%|
|3 Month Change||-66.19%|
|1 Year Change||-89.57%|
|3 Year Change||-91.64%|
|5 Year Change||-92.97%|
|Change since IPO||-98.14%|
Recent News & Updates
AGTC receives positive feedback from FDA for manufacturing facility
Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Applied Genetic Technologies proposes stock offering to fund clinical trials
Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering
|AGTC||US Biotechs||US Market|
Return vs Industry: AGTC underperformed the US Biotechs industry which returned -22.7% over the past year.
Return vs Market: AGTC underperformed the US Market which returned -20% over the past year.
|AGTC Average Weekly Movement||17.4%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: AGTC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: AGTC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease.
Applied Genetic Technologies Fundamentals Summary
|AGTC fundamental statistics|
Is AGTC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGTC income statement (TTM)|
|Cost of Revenue||US$21.76m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.02|
|Net Profit Margin||-21,213.23%|
How did AGTC perform over the long term?See historical performance and comparison
Is AGTC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AGTC?
Other financial metrics that can be useful for relative valuation.
|What is AGTC's n/a Ratio?|
Price to Book Ratio vs Peers
How does AGTC's PB Ratio compare to its peers?
|AGTC PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
IDRA Idera Pharmaceuticals
CYCC Cyclacel Pharmaceuticals
ENZN Enzon Pharmaceuticals
CRBP Corbus Pharmaceuticals Holdings
AGTC Applied Genetic Technologies
Price-To-Book vs Peers: AGTC is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (2x).
Price to Earnings Ratio vs Industry
How does AGTC's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: AGTC is good value based on its Price-To-Book Ratio (0.6x) compared to the US Biotechs industry average (1.7x)
Price to Book Ratio vs Fair Ratio
What is AGTC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.6x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate AGTC's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of AGTC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AGTC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AGTC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Applied Genetic Technologies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGTC's revenue (47.6% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: AGTC's revenue (47.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGTC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Applied Genetic Technologies performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGTC is currently unprofitable.
Growing Profit Margin: AGTC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGTC is unprofitable, and losses have increased over the past 5 years at a rate of 43.7% per year.
Accelerating Growth: Unable to compare AGTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: AGTC has a negative Return on Equity (-233.89%), as it is currently unprofitable.
Discover strong past performing companies
How is Applied Genetic Technologies's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AGTC's short term assets ($49.6M) exceed its short term liabilities ($25.2M).
Long Term Liabilities: AGTC's short term assets ($49.6M) exceed its long term liabilities ($12.0M).
Debt to Equity History and Analysis
Debt Level: AGTC has more cash than its total debt.
Reducing Debt: Insufficient data to determine if AGTC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGTC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AGTC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22.7% each year
Discover healthy companies
What is Applied Genetic Technologies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Applied Genetic Technologies Dividend Yield vs Market|
|Company (Applied Genetic Technologies)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.5%|
|Industry Average (Biotechs)||2.7%|
|Analyst forecast in 3 Years (Applied Genetic Technologies)||n/a|
Notable Dividend: Unable to evaluate AGTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGTC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGTC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AGTC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sue Washer (61 yo)
Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...
CEO Compensation Analysis
|Sue Washer's Compensation vs Applied Genetic Technologies Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||n/a||n/a|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||US$1m||US$530k|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||n/a||n/a|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||US$988k||US$530k|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||n/a||n/a|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||US$1m||US$514k|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||n/a||n/a|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||US$1m||US$502k|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||n/a||n/a|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||US$1m||US$487k|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||n/a||n/a|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||US$2m||US$464k|
Compensation vs Market: Sue's total compensation ($USD1.44M) is above average for companies of similar size in the US market ($USD772.75K).
Compensation vs Earnings: Sue's compensation has increased whilst the company is unprofitable.
Experienced Management: AGTC's management team is seasoned and experienced (7.8 years average tenure).
Experienced Board: AGTC's board of directors are considered experienced (9.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|01 Jul 22||SellUS$6,250||Stephen Potter||Individual||8,070||US$0.77|
|27 May 22||SellUS$3,376||Gerald Reynolds||Individual||3,994||US$0.85|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57.8%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Applied Genetic Technologies Corporation's employee growth, exchange listings and data sources
- Name: Applied Genetic Technologies Corporation
- Ticker: AGTC
- Exchange: NasdaqGM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$18.552m
- Shares outstanding: 67.63m
- Website: https://agtc.com
Number of Employees
- Applied Genetic Technologies Corporation
- 14193 NW 119th Terrace
- Suite 10
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AGTC||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Mar 2014|
|2GT||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2014|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/04 00:00|
|End of Day Share Price||2022/10/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.